Annex I questions and answers – Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

Submitted by Anonymous (not verified) on 20 January 2025 - 10:56

Annex I questions and answers – Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

Human medicines European public assessment report (EPAR): Ocaliva, obeticholic acid, Date of authorisation: 12/12/2016, Revision: 21, Status: Revoked

Submitted by Anonymous (not verified) on 20 January 2025 - 8:50

Human medicines European public assessment report (EPAR): Ocaliva, obeticholic acid, Date of authorisation: 12/12/2016, Revision: 21, Status: Revoked

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 8, Status: Withdrawn

Submitted by Anonymous (not verified) on 17 January 2025 - 16:15

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 8, Status: Withdrawn

Human medicines European public assessment report (EPAR): Kinzalkomb, telmisartan,hydrochlorothiazide, Date of authorisation: 19/04/2002, Revision: 41, Status: Authorised

Submitted by Anonymous (not verified) on 17 January 2025 - 15:05

Human medicines European public assessment report (EPAR): Kinzalkomb, telmisartan,hydrochlorothiazide, Date of authorisation: 19/04/2002, Revision: 41, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More